FI102610B1 - Menetelmä farmakologisesti aktiivisten imidatsolyylialkeenihappojen valmistamiseksi - Google Patents

Menetelmä farmakologisesti aktiivisten imidatsolyylialkeenihappojen valmistamiseksi

Info

Publication number: FI102610B1
Authority: FI; Finland
Prior art keywords: imidazolylalkenoic; acids; preparation; pharmacologically active; angiotensin
Prior art date: 1989-06-14

Application number

FI902970A

Other languages

English (en)

Swedish (sv)

Other versions

FI102610B (fi

FI902970A0 (fi

Inventor

Joseph Alan Finkelstein

Joseph Weinstock

Keenan Richard Mcculloch

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-14

Filing date

1990-06-13

Publication date

1999-01-15

1990-06-13 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1990-06-13 Publication of FI902970A0 publication Critical patent/FI902970A0/fi

1999-01-15 Application granted granted Critical

1999-01-15 Publication of FI102610B publication Critical patent/FI102610B/fi

1999-01-15 Publication of FI102610B1 publication Critical patent/FI102610B1/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Polishing Bodies And Polishing Tools (AREA)
External Artificial Organs (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

FI902970A 1989-06-14 1990-06-13 Menetelmä farmakologisesti aktiivisten imidatsolyylialkeenihappojen valmistamiseksi FI102610B1 (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US36607989A	1989-06-14	1989-06-14
US36607989		1989-06-14
US50641290A	1990-04-06	1990-04-06
US50641290		1990-04-06

Publications (3)

Publication Number	Publication Date
FI902970A0 FI902970A0 (fi)	1990-06-13
FI102610B FI102610B (fi)	1999-01-15
FI102610B1 true FI102610B1 (fi)	1999-01-15

Family

ID=27003220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI902970A FI102610B1 (fi)	1989-06-14	1990-06-13	Menetelmä farmakologisesti aktiivisten imidatsolyylialkeenihappojen valmistamiseksi

Country Status (25)

Country	Link
EP (2)	EP0403159B1 (fi)
JP (1)	JPH0768223B2 (fi)
KR (1)	KR0165837B1 (fi)
CN (2)	CN1027504C (fi)
AT (2)	ATE250587T1 (fi)
CA (1)	CA2018438C (fi)
CY (1)	CY2232B1 (fi)
DE (3)	DE69034103T2 (fi)
DK (2)	DK0955294T3 (fi)
ES (2)	ES2142789T3 (fi)
FI (1)	FI102610B1 (fi)
GR (1)	GR3033452T3 (fi)
HU (1)	HU208537B (fi)
IE (2)	IE20000297A1 (fi)
IL (1)	IL94698A (fi)
LU (1)	LU90562I2 (fi)
MA (1)	MA21896A1 (fi)
NL (1)	NL300006I2 (fi)
NO (1)	NO175977C (fi)
NZ (1)	NZ233997A (fi)
PH (1)	PH27592A (fi)
PL (3)	PL165609B1 (fi)
PT (1)	PT94377B (fi)
SG (1)	SG52330A1 (fi)
ZW (1)	ZW9490A1 (fi)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5210079A (en) *	1988-01-07	1993-05-11	E. I. Du Pont De Nemours And Company	Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5185351A (en) *	1989-06-14	1993-02-09	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5449682A (en) *	1990-02-13	1995-09-12	Merck & Co., Inc.	Angiotensin II antagonists incorporating a substituted benzyl element
DE122010000024I1 (de) *	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
DE69123582T2 (de) *	1990-06-22	1997-05-15	E.I. Du Pont De Nemours & Co., Wilmington, Del.	Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
NZ238688A (en) *	1990-06-28	1992-05-26	Smithkline Beecham Corp	Substituted histidines: pharmaceutical compositions, preparation and uses thereof
NZ239161A (en) *	1990-07-31	1994-01-26	Smithkline Beecham Corp	Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
GB9027197D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
WO1992010189A1 (en) *	1990-12-14	1992-06-25	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids
US6025380A (en) *	1990-12-14	2000-02-15	Smithkline Beecham Plc	Medicament
GB9027199D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
GB9027198D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
US6028091A (en) *	1990-12-14	2000-02-22	Smithkline Beecham Plc	Medicament
GB9027208D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
GB9027211D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
GB9027210D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
GB9027212D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
GB9027209D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
US6034114A (en) *	1990-12-14	2000-03-07	Smithkline Beecham Plc	Medicament
GB9027200D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
GB9027201D0 (en) *	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
US5656650A (en) *	1990-12-14	1997-08-12	Smithkline Beecham Corp.	Angiotensin II receptor blocking compositions
WO1992010097A1 (en) *	1990-12-14	1992-06-25	Smithkline Beecham Corporation	Angiotensin ii receptor blocking compositions
US5236928A (en) *	1991-03-19	1993-08-17	Merck & Co., Inc.	Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
EP0505098A1 (en) *	1991-03-19	1992-09-23	Merck & Co. Inc.	Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists
US5187179A (en) *	1991-03-22	1993-02-16	Merck & Co., Inc.	Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
US5128327A (en) *	1991-03-25	1992-07-07	Merck & Co., Inc.	Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5177074A (en) *	1991-03-26	1993-01-05	Merck & Co., Inc.	Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5252574A (en) *	1991-04-26	1993-10-12	Merck & Co., Inc.	Angiotensin II antagonists incorporating a substituted thiophene or furan
US5198438A (en) *	1991-05-07	1993-03-30	Merck & Co., Inc.	Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5447949A (en) *	1991-05-15	1995-09-05	Smithkline Beecham Corporation	N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
GB9110532D0 (en) *	1991-05-15	1991-07-03	Smithkline Beecham Corp	Chemical compounds
GB9110636D0 (en) *	1991-05-16	1991-07-03	Glaxo Group Ltd	Chemical compounds
US5175164A (en) *	1991-06-05	1992-12-29	Merck & Co., Inc.	Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
DE4132633A1 (de) *	1991-10-01	1993-04-08	Bayer Ag	Cyclisch substituierte imidazolyl-propensaeurederivate
DE4132631A1 (de) *	1991-10-01	1993-04-08	Bayer Ag	Imidazolyl-propensaeurederivate
DE4132632A1 (de) *	1991-10-01	1993-04-08	Bayer Ag	Substituierte imidazolyl-propensaeurederivate
GB9121463D0 (en) *	1991-10-10	1991-11-27	Smithkline Beecham Corp	Medicament
US5389661A (en) *	1991-12-05	1995-02-14	Warner-Lambert Company	Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en) *	1991-12-05	1994-06-21	Warner-Lambert Company	Imidazole with angiotensin II antagonist properties
US5308853A (en) *	1991-12-20	1994-05-03	Warner-Lambert Company	Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5240953A (en) *	1992-01-30	1993-08-31	Ortho Pharmaceutical Corporation	Substituted triazoles as angiotensin ii inhibitors
FR2687674B1 (fr) *	1992-02-07	1995-05-19	Roussel Uclaf	Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
DE4206043A1 (de) *	1992-02-27	1993-09-02	Bayer Ag	Sulfonylbenzyl-substituierte imidazole
DE4206041A1 (de) *	1992-02-27	1993-09-02	Bayer Ag	Sulfonylbenzyl-substituierte imidazolylpropensaeurederivate
DE4206042A1 (de) *	1992-02-27	1993-09-02	Bayer Ag	Sulfonylbenzyl-substituierte imidazopyridine
DE4206045A1 (de) *	1992-02-27	1993-09-02	Bayer Ag	Sulfonylbenzyl substituierte pyridone
US5364869A (en) *	1992-03-09	1994-11-15	Abbott Laboratories	Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
FR2689508B1 (fr) *	1992-04-01	1994-06-17	Fournier Ind & Sante	Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
DE4210787A1 (de) *	1992-04-01	1993-10-07	Bayer Ag	Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
DE4212796A1 (de) *	1992-04-16	1993-10-21	Bayer Ag	Propenoyl-imidazolderivate
DE4215587A1 (de) *	1992-05-12	1993-11-18	Bayer Ag	Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
DE4215588A1 (de) *	1992-05-12	1993-11-18	Bayer Ag	Biphenylmethyl-substituierte Pyridone
DE4319041A1 (de) *	1992-10-23	1994-04-28	Bayer Ag	Trisubstituierte Biphenyle
FI964340A0 (fi) *	1994-04-29	1996-10-28	Pfizer	Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina
US20030004202A1 (en)	1997-04-28	2003-01-02	Smithkline Beecham Corporation	Endothelin receptor antagonists
AU3416995A (en) *	1994-09-02	1996-03-27	Smithkline Beecham Corporation	Endothelin receptor antagonists
PT853477E (pt) *	1995-10-06	2003-01-31	Novartis Ag	Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
JP2000502104A (ja) *	1995-12-21	2000-02-22	スミスクライン・ビーチャム・コーポレイション	エンドセリン受容体アンタゴニスト
ES2189940T3 (es)	1996-02-29	2003-07-16	Novartis Ag	Antagonista de receptor at1 para la estimulacion de la apoptosis.
AR011126A1 (es)	1997-02-14	2000-08-02	Smithkline Beecham Corp	Procedimiento para preparar eprosartano y compuestos intermediarios.
ES2221407T3 (es)	1998-07-18	2004-12-16	Bayer Cropscience Ag	Derivados de imidoamida.
ATE354364T1 (de)	1998-12-23	2007-03-15	Novartis Pharma Gmbh	Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
US6465502B1 (en)	1998-12-23	2002-10-15	Novartis Ag	Additional therapeutic use
CN101011390A (zh)	1999-01-26	2007-08-08	诺瓦提斯公司	血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
AR033390A1 (es)	2000-08-22	2003-12-17	Novartis Ag	Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR20060056352A (ko) *	2003-07-31	2006-05-24	니콕스 에스. 에이.	안지오텐신ⅱ 수용체 차단제 유도체들
GB0327839D0 (en)	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
GB0402262D0 (en)	2004-02-02	2004-03-10	Novartis Ag	Process for the manufacture of organic compounds
NZ549535A (en)	2004-03-17	2010-11-26	Novartis Ag	Use of aliskiren for treating renal and other disorders
BRPI0516128A (pt)	2004-10-08	2008-08-26	Novartis Ag	uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
KR101021828B1 (ko)	2004-10-27	2011-03-17	다이이찌 산쿄 가부시키가이샤	2 이상의 치환기를 갖는 벤젠 화합물
EP2481408A3 (en)	2007-03-01	2013-01-09	Probiodrug AG	New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en)	2008-07-16	2011-10-11	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8450525B2 (en) *	2007-10-22	2013-05-28	Orchid Chemicals & Pharmaceuticals Limited	Histone deacetylase inhibitors
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AR072477A1 (es) *	2008-07-11	2010-09-01	Solvay Pharm Bv	Formulacion farmaceutica de eprosartan. uso.
WO2011004384A2 (en)	2009-06-05	2011-01-13	Glochem Industries Limited	Process for the preparation of eprosartan
CA2772488C (en)	2009-09-11	2018-04-17	Probiodrug Ag	Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja)	2010-03-03	2016-11-16	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤
NZ602312A (en)	2010-03-10	2014-02-28	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja)	2010-04-21	2016-07-05	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2686313B1 (en)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
BR112014014527A2 (pt)	2011-12-15	2017-06-13	Takeda Pharmaceuticals Usa Inc	combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
CN102584628B (zh) *	2011-12-30	2015-04-22	浙江外国语学院	一种n-羧甲基戊脒的合成方法
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5671073A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	Imidazole derivative
JPS5671074A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS58157768A (ja) *	1982-03-16	1983-09-19	Takeda Chem Ind Ltd	４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
US4668794A (en) *	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
CA1334092C (en) *	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US4835154A (en) *	1987-06-01	1989-05-30	Smithkline Beckman Corporation	1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US4798843A (en) *	1987-07-09	1989-01-17	Smithkline Beckman Corporation	2-mercaproimidazole dopamine-β-hydroxylase inhibitors
CA1338238C (en) *	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids

1990
- 1990-06-07 SG SG1996002914A patent/SG52330A1/en unknown
- 1990-06-07 EP EP90306204A patent/EP0403159B1/en not_active Expired - Lifetime
- 1990-06-07 ES ES90306204T patent/ES2142789T3/es not_active Expired - Lifetime
- 1990-06-07 DK DK99115614T patent/DK0955294T3/da active
- 1990-06-07 AT AT99115614T patent/ATE250587T1/de not_active IP Right Cessation
- 1990-06-07 CA CA002018438A patent/CA2018438C/en not_active Expired - Lifetime
- 1990-06-07 DE DE69034103T patent/DE69034103T2/de not_active Expired - Lifetime
- 1990-06-07 EP EP99115614A patent/EP0955294B1/en not_active Expired - Lifetime
- 1990-06-07 ES ES99115614T patent/ES2207091T3/es not_active Expired - Lifetime
- 1990-06-07 DE DE69033469T patent/DE69033469T2/de not_active Expired - Lifetime
- 1990-06-07 DK DK90306204T patent/DK0403159T3/da active
- 1990-06-07 AT AT90306204T patent/ATE190051T1/de active
- 1990-06-07 DE DE2000175018 patent/DE10075018I2/de active Active
- 1990-06-08 ZW ZW94/90A patent/ZW9490A1/xx unknown
- 1990-06-08 NZ NZ233997A patent/NZ233997A/en unknown
- 1990-06-11 PH PH40649A patent/PH27592A/en unknown
- 1990-06-11 IL IL9469890A patent/IL94698A/en unknown
- 1990-06-12 PL PL90285591A patent/PL165609B1/pl unknown
- 1990-06-12 PL PL90301864A patent/PL166722B1/pl unknown
- 1990-06-12 PL PL90301863A patent/PL166669B1/pl unknown
- 1990-06-12 PT PT94377A patent/PT94377B/pt not_active IP Right Cessation
- 1990-06-13 MA MA22145A patent/MA21896A1/fr unknown
- 1990-06-13 NO NO902632A patent/NO175977C/no not_active IP Right Cessation
- 1990-06-13 FI FI902970A patent/FI102610B1/fi active IP Right Grant
- 1990-06-13 IE IE20000297A patent/IE20000297A1/en unknown
- 1990-06-13 IE IE214090A patent/IE902140A1/en not_active IP Right Cessation
- 1990-06-14 HU HU903847A patent/HU208537B/hu unknown
- 1990-06-14 CN CN90104438A patent/CN1027504C/zh not_active Expired - Lifetime
- 1990-06-14 JP JP2156627A patent/JPH0768223B2/ja not_active Expired - Lifetime
- 1990-06-14 KR KR1019900008739A patent/KR0165837B1/ko not_active Expired - Lifetime
1993
- 1993-03-16 CN CN93103111A patent/CN1048159C/zh not_active Expired - Lifetime
2000
- 2000-04-05 LU LU90562C patent/LU90562I2/xx unknown
- 2000-05-16 NL NL300006C patent/NL300006I2/nl unknown
- 2000-05-19 GR GR20000401140T patent/GR3033452T3/el not_active IP Right Cessation
2001
- 2001-09-03 CY CY0100023A patent/CY2232B1/xx unknown

Also Published As

Publication number	Publication date
LU90562I2 (fr)	2000-06-05
CN1027504C (zh)	1995-01-25
NL300006I1 (nl)	2000-07-03
PL285591A1 (en)	1991-03-25
DE69033469T2 (de)	2000-09-07
FI102610B (fi)	1999-01-15
PT94377B (pt)	1997-02-28
CA2018438A1 (en)	1990-12-14
GR3033452T3 (en)	2000-09-29
EP0403159B1 (en)	2000-03-01
PL166669B1 (pl)	1995-06-30
HK1025315A1 (en)	2000-11-10
NL300006I2 (nl)	2000-10-02
EP0955294B1 (en)	2003-09-24
CN1048038A (zh)	1990-12-26
HU208537B (en)	1993-11-29
IE902140A1 (en)	1991-01-02
HUT55011A (en)	1991-04-29
PL165609B1 (pl)	1995-01-31
AU5690190A (en)	1991-01-10
SG52330A1 (en)	1998-09-28
JPH03115278A (ja)	1991-05-16
DE10075018I1 (de)	2000-09-21
NO902632D0 (no)	1990-06-13
ES2207091T3 (es)	2004-05-16
IE20000297A1 (en)	2000-12-13
NZ233997A (en)	1991-04-26
EP0955294A3 (en)	2000-04-19
DK0403159T3 (da)	2000-08-14
PL166722B1 (pl)	1995-06-30
ATE190051T1 (de)	2000-03-15
NO175977B (no)	1994-10-03
HU903847D0 (en)	1990-11-28
HK1012384A1 (en)	1999-07-30
NO902632L (no)	1990-12-17
CY2232B1 (en)	2003-04-18
CA2018438C (en)	2000-08-08
PT94377A (pt)	1991-03-20
IL94698A (en)	1994-07-31
FI902970A0 (fi)	1990-06-13
PH27592A (en)	1993-08-31
DE69033469D1 (de)	2000-04-06
IL94698A0 (en)	1991-04-15
KR0165837B1 (ko)	1999-02-18
EP0955294A2 (en)	1999-11-10
DE10075018I2 (de)	2001-08-09
CN1048159C (zh)	2000-01-12
NO175977C (no)	1995-01-11
DK0955294T3 (da)	2004-02-02
ES2142789T3 (es)	2000-05-01
ZW9490A1 (en)	1990-10-31
DE69034103T2 (de)	2004-07-15
ATE250587T1 (de)	2003-10-15
MA21896A1 (fr)	1991-04-01
JPH0768223B2 (ja)	1995-07-26
AU633322B2 (en)	1993-01-28
EP0403159A3 (en)	1991-12-27
KR910000658A (ko)	1991-01-29
EP0403159A2 (en)	1990-12-19
DE69034103D1 (de)	2003-10-30
IE902140L (en)	1990-12-14
CN1079649A (zh)	1993-12-22

Publication	Publication Date	Title
FI102610B1 (fi)	1999-01-15	Menetelmä farmakologisesti aktiivisten imidatsolyylialkeenihappojen valmistamiseksi
ES2062403T3 (es)	1994-12-16	5-((tetrazolil)-alquenil)-imidazoles sustituidos.
HU907025D0 (en)	1991-05-28	Process for producing substituted n-(imidazolyl-alkyl)-alanine derivatives and pharmaceutical preparatives containing these compounds as active substance

Legal Events

Date	Code	Title	Description
1990-06-13	FG	Patent granted	Owner name: SMITHKLINE BEECHAM CORPORATION
2004-08-31	FG	Patent granted	Owner name: SMITHKLINE BEECHAM CORPORATION